Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “IMMUNE TOLERANCE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1994

[Immune tolerance].

Immune tolerance reflects the absence of immune reactions to self-antigens (natural tolerance) or exogenous antigens, at least in experimental models (acquired tolerance). It results in part from central mechanisms leading to the elimination or deletion of auto-reactive B or T cell clones by apoptosis in primary lymphoid organs. In the periphery, this is reflected by more-or-less reversible states of anergy, which arise from a time or spatial discordance between the different signals required for lymphocyte activation, or from a network of interactions between lymphocytes leading to the production of antagonistic signals. The reversibility of anergy-inducing mechanisms, a deregulation of the production of certain cytokines, or incomplete clonal deletion mechanisms could explain the emergence of autoimmune diseases by a rupture of self-tolerance. As these mechanisms are not fully understood, clinical induction of tolerance by the use of nonspecific immunodepressive agents is not yet possible.

Animals↗
PubMed2006

The regulatory role of dendritic cells in the immune tolerance.

Immune homeostasis is important for the protection of a host from pathogen aggression, as well as for preventing autoimmunity. Dendritic cells (DCs), the most potent antigen presenting cells, are critical in innate, adaptive immunity and in central tolerance. Recently, their involvement in peripheral tolerance has been shown. Whether DCs induce immunity or tolerance depends on their state of maturation. Different subsets of tolerogenic DCs have been identified in vivo, either in physiological, or pathological conditions, such as tumors, or GVHD. Moreover, tolerogenic DCs can be generated in vitro, by using different culture conditions, such as IL-10 or TGF-beta. In our study, we obtained tolerogenic DCs, by culturing them in the presence of human mesenchymal stem cells (MSCs).

Animals↗
PubMed1999

Comparison of the international immune tolerance registry and the North American immune tolerance registry.

Two immune tolerance registries--the International Immune Tolerance Study Group (ITSG) and North American Immune Tolerance Study (NAITS) - are compared and findings from combined data reported. The registries differed with respect to data collection tools, location, host and environmental factors, start date distribution and treatment products. The success and failure rates were similar in the two studies. There was a highly significant association between maximum historical titre and immune tolerance success; the success rate decreased as the historical titre increased. There was a significant association between inhibitor titre immediately prior to treatment and the probability for treatment success, and between outcome and time from diagnosis to treatment in the ITSG (of borderline significance in the NAITS). There was a significant association between outcome and dose, though the direction of the associations was not the same. In the ITSG, success was associated with doses greater than or equal to 200 IU/kg/day, while in the NAITS, greater success was observed with doses of less than 50 IU/kg/day. There was no association between outcome and treatment product. Data from the two registries were combined to produce a table for calculating the chance of successful treatment by historical titre, pretreatment titre, and dose.

Adult↗
PubMed2001

The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic.

The development of effective, new, biologically based therapies for RA has created real excitement and justifiable optimism in recent years among rheumatologists and among patients with rheumatic diseases. Recent advances in our understanding of the mechanisms of immune activation and immune tolerance provide further cause for optimism. Against this background, the establishment of the ITN is an important step. However, significant hurdles remain to be cleared. First, despite dramatic scientific progress, restoration of immune tolerance in the face of an established autoimmune response is still an elusive goal, even in the laboratory. Not only does the ITN face this fundamental scientific challenge, but it also faces daunting practical and political challenges. For example, can the ITN influence the research agenda of the pharmaceutical and biotechnology industries? This question and other important questions will only be answered as the ITN matures. Autoimmune disease, although individually uncommon, affects more than 2% of Americans. The rheumatologist is especially aware of the devastating potential of autoimmune diseases. If the ITN succeeds in linking basic research into the mechanisms of autoimmunity with clinical trials of promising new therapies, it can be expected to play a critical role in advancing the practice of clinical rheumatology.

Animals↗
PubMed2000

The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.

The North American Immune Tolerance Registry (NAITR) was initiated with the goal of determining, by questionnaire, immune tolerance (ITT) practices in hemophilia treatment centers in Canada and the United States. Sixty-eight centers (40%) responded. Of the 130 registry subjects with hemophilia A who completed ITT, 93 (72%) achieved tolerance. Of the 11 completed ITT courses in patients with hemophilia B, 4 (36%) were successful. Maintenance therapy was defined as any dotting factor regimen administered subsequent to the patient achieving the treating physician's criteria for successful immune tolerance. Seventy-five (81%) of 93 individuals in the hemophilia A cohort who successfully achieved tolerance were maintained on a regular (prophylactic factor VIII (FVIII) regimen for a variable time period post-ITT. The median dose used was 150 units/kg/week (range: 17-700). Forty-eight (64%) subjects remained tolerant while receiving regular doses of FVIII for a median observation period of 13 months (range 0-129 months). Of 27 patients whose maintenance therapy had been stopped, 17 (68%) remained tolerant over a median period of 19 months (range 1-54 months) and 9 relapsed. Among the relapses, 3 occurred after maintenance therapy was stopped; 6 were noted on prophylactic FVIII at a median time of 11 months (range 2-61 months). The definition of tolerance was reviewed for the 9 subjects who relapsed and was defined by a normal recovery and survival in only 1/9 patients. Among the 11 hemophilia B subjects in the cohort who completed tolerance, 4 had a successful outcome. Four individuals were placed on maintenance regimens of 25-100 units FIX/kg/day and all remained tolerant.

Factor IX↗
PubMed2006

Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B.

Based on virological and biochemical parameters patients with chronic hepatitis B virus (HBV) are divided into distinct clinical phases: the immune-tolerance phase, the immune-clearance phase, and the inactive carrier state. Unclear is whether these phases have characteristic intrahepatic immune responses. The composition of liver-derived lymphocytes in patients with chronic HBV infection was studied. In 47 patients the composition of liver-derived lymphocytes was analyzed by flow cytometry of fine needle aspiration biopsies of the liver. The proportion natural killer (NK) cells in the liver was significantly higher in immune-tolerant than in immune-clearance patients and inactive carriers. No differences were found in proportion CD4+ T-cells and CD8+ T-cells, in these phases. However, when patients in the immune-clearance phase, with similar alanine transaminase (ALT), were grouped according to viral load, the proportion CD8+ T-cells was higher in those with high viral load. In contrast, the proportion CD4+ T-cells was increased in patients with low HBV-DNA. These differences were absent in the peripheral blood (PB). Intrahepatic HBV-specific CD8+ T-cells were mainly found in immune-clearance patients with low viral load. In conclusion, clear differences in the intrahepatic cellular infiltrate were found between the various clinical phases of chronic HBV infection. These findings are relevant to the design of new, individualized anti-viral strategies.

Adolescent↗
PubMed2006

The two simultaneously occurring processes in one immune response: the positive immune reaction and immune tolerance.

The immune response is tightly shaped by both positive and negative signals on different levels. Based on the accumulating data, we hypothesize that, both immune reaction and immune tolerance processes were potentially and simultaneously triggered after antigen challenging. The actual outcome of immune response is dependent on the sum of these two reactions. The hypothesis, if proved to be correct, will significantly improve our understanding the immunity and its related pathological effects. It will influence our choice on immunosuppressive drugs for patients with transplant grafts, autoimmune diseases. As the immunosuppressive drugs may also block the potential immune tolerance process which is beneficial to the patients. Therefore, we should try to develop novel immunosuppressive medicines that selectively inhibit immune reaction but no effects on immune tolerance for patients with allo-grafts or autoimmune diseases. On the other hand, it will impact the immunotherapy for tumors and the development of vaccines.

Humans↗
PubMedDate not supplied

[Relationship between orally induced immune tolerance and local immune response (author's transl)].

BALB/c mice were immunized by intragastric immunization with sheep red blood cells repeated daily for 4 days. This immunization resulted in the appearance of circulating antibodies which were predominantly of the IgA class. When serum from intragastrically immunized mice was administered intraperitoneally to recipient animals 8 h before parenteral immunization with sheep red blood cells, the subsequent immune response was depressed proportionally to the dose of serum injected. When intragastrically immunized mice were challenged intraperitoneally with sheep red blood cells, the level of the IgM response to the parenteral stimulation was in inverse ratio to the IgA response induced by the oral route. These results suggest that orally induced IgA production is related to orally induced immune tolerance and that systemic hyporesponsiveness is achieved while gut plasma cells are producing specific IgA.

Administration, Oral↗
PubMed2006

[Immune tolerance after renal transplantation].

Progress in immunosuppressive therapy has improved short-term survival of renal allografts by decreasing the frequency of acute rejections. However, the long-term survival of renal grafts has not improved. Transplanted kidneys are lost in the late period after transplantation as a result of vasculopathy and chronic rejection. Immunological tolerance means the lack of immunological activity towards certain antigens while the response towards others remains correct. The induction of immunological tolerance of donor antigens (transplant tolerance) is examined intensively to work out treatment methods which will allow prevention of chronic allograft rejection. The paper includes an overview of current knowledge on allograft tolerance. Immune response to alloantigens is described and the mechanisms of immunological tolerance induction (including clonal deletion, anergy connected with the microchimerism phenomenon, and active suppression caused by regulatory lymphocytes) are characterized. The role of dendritic cells in the process of inducing and maintaining tolerance is highlighted. Tolerance-inducing strategies in renal transplant recipients and clinically applied evaluation methods are presented. At present, optimizing recipient matching is used to decrease the risk of graft rejection. Hopefully, gene therapy will be possible in the near future. However, before introducing such a procedure into clinical studies, optimal therapy conditions and risk evaluation must be defined in tests on animals.

Animals↗
PubMed2003

Mechanisms of peripheral immune tolerance: conversion of the immune to the unresponsive phenotype.

Our studies on the immune response to foreign antigens are reviewed as they relate to the mechanisms of peripheral immune tolerance. The activation of suppressor T cells by distinct modes of antigen presentation is discussed. Through the use of mice expressing transgenic T-cell receptors specific for foreign antigens, we have concluded that the separable mechanisms of anergy and active suppression by CD25+ T cells work in concert to produce peripheral tolerance. In T-cell receptor Vbeta8.1 transgenic mice rendered tolerant of Mls-1a, the absence of the cell surface marker 6C10 defines the anergic population of CD4+ T cells, while 6C10+ CD4+ T cells are actively suppressed by CD25+ T cells. Through discussion of these observations, we have developed a historical perspective on recent advances in the understanding of mechanisms of peripheral tolerance.

Animals↗
PubMed2002

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies.

Immune tolerance therapies are designed to reprogram immune cells in a highly specific fashion to eliminate pathogenic responses while preserving protective immunity. A concept that has tantalized immunologists for decades, the development of tolerance-inducing therapies, would revolutionize the management of a wide range of chronic and often debilitating diseases by obviating the need for lifelong immunosuppressive regimens. The advances of the past decade have provided a more detailed understanding of the molecular events associated with T-cell recognition and activation. Building on these advances, immunologists have demonstrated the feasibility of various tolerance-inducing approaches in small- and large-animal models of autoimmunity, allergy, and transplant graft rejection. Unprecedented opportunities to test these approaches in a variety of human diseases have now emerged. To capitalize on these advances, the National Institutes of Health recently established the Immune Tolerance Network (ITN), an international consortium of more than 70 basic and clinical immunologists dedicated to the evaluation of novel tolerance-inducing therapies and associated studies of immunologic mechanisms. By using a unique interactive approach to accelerate the development of clinical tolerance therapies, the ITN is partnering with the biotechnology and pharmaceutical industries to examine innovative tolerogenic approaches in a range of allergic and autoimmune diseases and to prevent graft rejection after transplantation. Two years since its inception, the ITN now has approximately 2 dozen clinical trials or tolerance assays studies ongoing or in later stages of protocol development. This report summarizes the rationale for emphasizing clinical research on immune tolerance and highlights the progress of the ITN.

Autoimmune Diseases↗